Philogen SpA (PHIL) AI Stock Analysis

• Market Cap: €690.13M
• Dividend Yield: N/A
• Average Volume (3M): 11.76K
• Price to Earnings (P/E): 21.4
• Beta (1Y): -0.09
• Revenue Growth: 219.91%
• EPS Growth: N/A
• Country: IT
• Employees: 174
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 29,242,860
• 10 Day Avg. Volume: 20,418
• 30 Day Avg. Volume: 11,758
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €30.00
• Price Target Upside: 27.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 74 Outperform
• Price Target: €26.00 ▲(10.64% Upside)

Philogen SpA's strong financial performance is the most significant factor, driven by revenue growth, improved margins, and a debt-free balance sheet. Technical analysis shows a positive trend, though some indicators suggest caution. The valuation is reasonable, but the lack of a dividend yield may deter some investors.

Positive Factors

Financial Growth

Philogen anticipates tripling its revenues through its partnership agreement with Sun Pharma, indicating strong financial growth prospects.

Licensing Agreement

Philogen's global licensing agreement with RayzeBio for OncoACP3 boosts investor confidence in its innovation capabilities beyond existing products.

Negative Factors

Market Perception

Analyst views Philogen's late-stage pipeline as underappreciated by the market, suggesting potential undervaluation of its stock.

Philogen SpA Business Overview & Revenue Model

Company Description

Philogen SpA (PHIL) is a biotechnology company focused on the discovery and development of innovative biopharmaceutical products for the treatment of various diseases, with a particular emphasis on cancer and chronic inflammatory conditions. The company leverages its proprietary technologies to develop targeted therapies designed to selectively deliver bioactive agents to diseased tissues while sparing healthy ones. Philogen operates in the healthcare and biotechnology sectors, aiming to create novel therapies that offer significant benefits over existing treatment options.

How the Company Makes Money

Philogen SpA generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company's revenue streams include licensing agreements, where they collaborate with larger pharmaceutical companies to further develop and market their drug candidates. Philogen may receive upfront payments, milestone payments based on the progress of clinical trials and regulatory approvals, and royalties on sales of successfully commercialized products. Additionally, the company may engage in research and development collaborations and partnerships that provide funding and shared resources, contributing to its earnings. Philogen's focus on developing targeted therapies allows it to position itself in niche markets with high unmet medical needs, potentially leading to premium pricing for its innovative treatments.

Philogen SpA Financial Statement Overview

Summary

Philogen SpA demonstrates excellent financial performance in 2024, with significant revenue growth, improved margins, and a strong balance sheet with no debt. Cash flows are robust, supporting operational and investment activities. The overall financial health is solid, positioning the company well for future growth.

Income Statement

Philogen SpA shows strong revenue growth with a significant increase from €23.1M in 2023 to €77.6M in 2024. The gross profit margin improved drastically from 24.5% in 2023 to 53.6% in 2024. The company turned profitable with a net profit margin of 58.3% in 2024, a remarkable recovery from previous losses. EBIT and EBITDA margins also improved to 53.6% in 2024, reflecting efficient cost management.

Balance Sheet

The balance sheet is strong with no debt in 2024, improving the debt-to-equity ratio to 0. The equity ratio is robust at 88.4%, indicating a solid equity base. However, the total assets increased less significantly compared to equity, which may limit leverage opportunities.

Cash Flow

Philogen's free cash flow turned positive in 2024, with a substantial increase to €38.7M from a negative position in 2023. The operating cash flow to net income ratio is 0.90, indicating efficient cash generation relative to net earnings. The free cash flow to net income ratio is 0.85, showing strong cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.00M	23.13M	23.71M	2.50M	4.78M
Gross Profit	54.42M	5.67M	10.53M	-8.14M	-5.05M
EBITDA	44.75M	-2.05M	-1.19M	-12.98M	-10.53M
Net Income	45.29M	-6.16M	-5.38M	-15.72M	-13.29M
Balance Sheet
Total Assets	168.45M	119.27M	125.83M	132.75M	85.47M
Cash, Cash Equivalents and Short-Term Investments	113.73M	75.34M	86.20M	101.68M	61.94M
Total Debt	11.51M	14.91M	11.89M	11.84M	11.98M
Total Liabilities	29.80M	28.68M	27.91M	27.67M	29.80M
Stockholders Equity	138.66M	90.59M	97.92M	105.09M	55.67M
Cash Flow
Free Cash Flow	38.67M	-10.69M	-9.15M	-25.85M	-16.81M
Operating Cash Flow	40.84M	-4.82M	-4.94M	-19.03M	-13.16M
Investing Cash Flow	-22.28M	159.00K	24.20M	-47.77M	17.77M
Financing Cash Flow	-3.78M	-4.17M	-3.78M	63.05M	3.79M

Philogen SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Positive. The current price of 23.5 is above the 20-day moving average (MA) of 22.69, above the 50-day MA of 22.37, and above the 200-day MA of 20.75, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 57.85 is Neutral, neither overbought nor oversold. The STOCH value of 68.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHIL	74 Outperform	€690.13M	21.35	39.51%	―	219.91%	―
PHN	73 Outperform	€471.95M	28.54		2.08%	17.78%	63.72%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
GHC	―	€433.64M	19.52	6.75%	―	―	―
ARBS	―	€17.05M	12.85		5.12%	―	―
ERFO	―	€13.92M	40.31		―	―	―
SVS	―	€43.81M	7.82		―	―	―

Philogen SpA Corporate Events

Philogen Updates Share Buyback Program with Recent Purchases

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 4,373 shares from June 30 to July 4, 2025, at an average price of Euro 21.4587 per share, totaling Euro 93,838.90. Since the program’s inception, the company has acquired 27,448 shares, representing 0.0676% of its share capital, with a total expenditure of Euro 612,402.32. This strategic move is part of Philogen’s efforts to enhance shareholder value and reflects its ongoing commitment to optimizing its capital structure.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases

Philogen S.p.A. has announced an update on its share buyback program, purchasing 8,333 shares between June 23 and June 27, 2025, at an average price of Euro 22.9635 per share. This move reflects the company’s ongoing strategy to manage its share capital and potentially enhance shareholder value, as it now holds 355,225 ordinary shares, representing 0.8747% of its share capital.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Withdraws Nidlegy™ Application from EMA, Plans Resubmission

Philogen has decided to withdraw its marketing authorization application for Nidlegy™, a treatment for locally advanced melanoma, from the European Medicines Agency due to delays in providing necessary data. Despite this setback, Philogen remains confident in Nidlegy™’s efficacy and safety profile, and plans to resubmit the application with updated data to make the treatment available for both melanoma and non-melanoma skin cancer patients.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philochem Licenses Prostate Cancer Agent to RayzeBio in $1.35 Billion Deal

Philogen’s subsidiary, Philochem AG, has licensed the worldwide rights to OncoACP3, a new therapeutic and diagnostic agent for prostate cancer, to RayzeBio, a Bristol-Myers Squibb subsidiary, in a deal worth up to $1.35 billion plus royalties. This agreement marks a significant milestone, enhancing RayzeBio’s position in the radiopharmaceutical sector and promising a groundbreaking treatment option for prostate cancer, with Philochem receiving an initial payment and potential milestone payments, subject to regulatory approvals expected by the third quarter of 2025.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates on Share Buyback Program

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Releases Shareholders’ Meeting Minutes

Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,800 shares between May 19 and May 23, 2025, at an average price of Euro 22.30 per share, totaling Euro 40,140.00. Since the program’s inception, the company has acquired 13,952 shares, representing 0.0344% of its share capital, with a total value of Euro 309,433.85. This move is part of Philogen’s strategy to manage its capital structure and potentially increase shareholder value, reflecting confidence in its ongoing operations and future prospects.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 7,628 shares between May 12 and May 16, 2025, at an average price of Euro 22.3742 per share, totaling Euro 170,670.65. This move is part of a broader strategy to enhance shareholder value and demonstrates the company’s commitment to its investors. The buyback program, since its inception, has seen the acquisition of 12,152 shares, representing 0.0299% of the share capital, indicating Philogen’s proactive approach in managing its equity and reinforcing its market position.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,524 shares from May 7 to May 9, 2025, representing 0.0111% of its share capital at an average price of Euro 21.80 per share. This move is part of a broader strategy approved by the Board of Directors and Shareholders’ Meeting, reflecting the company’s commitment to enhancing shareholder value. As of May 9, 2025, Philogen holds a total of 336,674 ordinary shares, equating to 0.8290% of its share capital, indicating a strategic approach to managing its equity and potentially impacting its market positioning.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Reports Strong Financial Position and Progress in Clinical Trials

Philogen S.p.A. reported a positive net financial position of €93.574 million for the first quarter of 2025, despite a decrease from the previous quarter. The company is progressing with its main trials, Nidlegy™ and Fibromun, and has initiated a share buyback program. The Board of Directors has also reconstituted key committees and noted significant advancements in their industrial programs. These developments reflect Philogen’s strategic focus on expanding its clinical pipeline and maintaining financial stability, which could enhance its position in the biopharmaceutical industry.